DSE Analyst data: 2026-07-13

ADVENT

Advent Pharma Limited · Pharmaceuticals and Chemicals · Cat Z
44/100
Mixed
৳16.1

DSE Hexagon

Stands out for constructive price action and a solid balance sheet, held back by little dividend.

Value36Financial Health65Dividend4Quality51Momentum72Integrity38

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (3)

  • ⚠ Z-category — higher default/governance risk
  • ⚠ Earnings trending down
  • ⚠ Financial health deteriorating

Rewards (1)

  • ✓ Trades below estimated fair value

Score breakdown

Price history & performance

52-week high৳16.7
52-week low৳12.0
From 52w high-3.6%
Beta0.86
7D +0.0%
1M +9.5%
3M +13.4%
6M +22.9%
1Y +18.4%
YTD +20.1%

Shareholder returns vs DSEX

ADVENT+2.5%
DSEX+2.4%

ADVENT outperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility42.3%
Daily VaR (95%)-3.57%
Max drawdown (5y)-65.4%
Correlation to market0.58

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)64.6
MACDbearish
Bollingerinside bands (+1.3σ)
Price cycle (Wyckoff)MARKUP
Health trenddeteriorating
Flow pressureaccumulation

Valuation

Fair value13.0 (9.1-16.8)
Upside-20.00%
Dividend yield+0.30%
Fundamental verdictWATCH
ConfidenceLOW (re-rate ceiling, not target)

Ownership

Institutional holding12.6%
Foreign holding1.0%
Free float56.38%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳1,000mn
Paid-up capital৳931.33mn
Face value৳10
Market lot1
Outstanding shares93,132,732
Last AGM31-12-2025
Fiscal year end30-Jun
Reserve & surplus (ex-OCI)৳599mn
Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E
Jul 14, 2026 36.36 30.77
Jul 13, 2026 36.59 30.96
Jul 12, 2026 36.82 31.15
Jul 9, 2026 36.14 30.58
Jul 8, 2026 35.68 30.19
Jul 7, 2026 35.68 30.19

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

20250.5%
20241%
20232%
20222%
20212%
20192%
20182%

Earnings & NAV

YearEPSNAVDividend
2025 0.72 16.43 0.5%
2024 0.9 15.78 1%
2023 1.06 15.02 2%
2022 1.05 14.1 2%

Quarterly EPS — FY2026

Q10.15
Q20.09
Half-year0.24
Q30.09
Nine-month0.33

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳16.5
৳17.2
৳17.8
৳18.4

Support

৳16
৳15.2
৳14.5
৳14

Historical bounce zones

Apr 27, 2025: ৳12.7→৳15.7 +24%
May 28, 2025: ৳12.8→৳16.8 +31%
Aug 24, 2025: ৳14→৳17.2 +23%
Sep 22, 2025: ৳14.5→৳16.9 +17%
Nov 16, 2025: ৳11.5→৳13.9 +21%
Nov 23, 2025: ৳12.6→৳14.5 +15%
Dec 21, 2025: ৳12.7→৳15 +18%
Mar 8, 2026: ৳12.8→৳15 +17%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -4% / -0.7% / 3.9%
30-day 41% vs 42% market avg Typical move: -6.7% / -0.7% / 7.3%

Signals: Bearish Harami

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readWAIT (until clears both axes)
Reference stopn/a
Reference target
Timing notewatch; no fresh money

Elevated (score 165) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: ACCUMULATION (13% >200-MA, flow ACC). Z-cat. [fundamentals WATCH, payout 7.0%, yield 0.3%]

My notes

Educational market analysis for the Dhaka Stock Exchange. Descriptive information only — not investment advice, not a buy/sell recommendation, and not from a licensed advisor. Prices and analysis can be delayed or wrong; verify with your broker before acting.